绝经后外阴阴道萎缩的局部雌激素和非激素制剂：EMAS 临床指南。
Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.
机构信息
Department of Women's and Children's Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
Department of Obstetrics and Gynecology, University Hospital, Basel, Switzerland.
出版信息
Maturitas. 2021 Jun;148:55-61. doi: 10.1016/j.maturitas.2021.04.005. Epub 2021 Apr 14.
INTRODUCTION
Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships.
AIM
The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations.
MATERIALS AND METHODS
Literature review and consensus of expert opinion.
SUMMARY RECOMMENDATIONS
An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.
简介
外阴阴道萎缩（VVA）是一种由雌激素缺乏引起的慢性疾病。它影响了大约 50%的绝经后妇女，降低了她们的整体和性生活质量，以及人际关系的质量。
目的
本临床指南旨在为外阴阴道萎缩的管理制定个体化的局部雌激素和非激素制剂治疗方法。
材料和方法
文献回顾和专家意见的共识。
总结建议
外阴阴道萎缩的管理需要个体化的方法。局部低剂量雌激素是有效的，也可以缓解尿失禁和预防复发性尿路感染。只要女性认为这种治疗对她们有益，就不应拒绝长期使用局部雌激素，因为安全性数据令人安心。对于正在接受考虑为激素依赖性的癌症辅助内分泌治疗的女性，非激素制剂（润滑剂和保湿剂）应作为外阴阴道萎缩的一线治疗方法。它们可以长期使用。
Zotero 插件